Third Xiangya Hospital of Central South University - Urology, Changsha, China.
Andrologia. 2011 Jun;43(3):208-12. doi: 10.1111/j.1439-0272.2010.01091.x. Epub 2011 Mar 25.
The study evaluated the long-term efficacy and safety profiles of self-intracavernous injection of prostaglandin E1 (PGE1) for erectile dysfunction (ED). Four hundred and sixteen ED patients were treated with self-intracavernous injection of PGE1 from January 1998 to December 2007 in our outpatient service. Follow-up was made to investigate the efficacy and side effects of this treatment. It was found that 261 patients (62.7%) felt satisfied and kept using this treatment due to its advantages of satisfactory efficacy and reasonable expense. Twenty-seven of them (6.5%) got rid of PGE1 treatment after five times injections and did not need any other drugs to maintain satisfactory sexual lives. Two hundred and fourteen (51.4%) patients kept using this treatment for over 1 year, 26 (6.2%) over 5 years, 12 (2.9%) over 8 years and 7 (1.7%) over 10 years. The major complications of self-intracavernous injection of PGE1 include fibrosis of corpus cavernosum (three cases), ecchymosis associated with vascular injury due to injection (23 cases) and pain associated with injection (295 cases). There were no patients displaying priapism. It is concluded that self-intracavernous injection of PGE1 is a safe and effective treatment for ED with various aetiologies and a broad range of severity, and no serious complications were observed after long-term application.
该研究评估了前列腺素 E1（PGE1）自我海绵体内注射治疗勃起功能障碍（ED）的长期疗效和安全性。1998 年 1 月至 2007 年 12 月，我们的门诊为 416 例 ED 患者提供了 PGE1 自我海绵体内注射治疗。通过随访调查了这种治疗的疗效和副作用。结果发现，261 例（62.7%）患者因疗效满意且费用合理而感到满意并继续使用这种治疗方法。其中 27 例（6.5%）在接受 5 次注射后摆脱了 PGE1 治疗，不需要任何其他药物来维持满意的性生活。214 例（51.4%）患者持续使用该治疗方法超过 1 年，26 例（6.2%）超过 5 年，12 例（2.9%）超过 8 年，7 例（1.7%）超过 10 年。PGE1 自我海绵体内注射的主要并发症包括海绵体纤维化（3 例）、因注射导致的血管损伤瘀斑（23 例）和注射相关疼痛（295 例）。无患者发生阴茎异常勃起。结论：PGE1 自我海绵体内注射治疗各种病因和不同严重程度的 ED 是一种安全有效的方法，长期应用无严重并发症。
